AI-fo­cused No­table Labs score $40M in fund­ing; Seat­tle Ge­net­ics/Astel­las sub­mit mar­ket­ing ap­pli­ca­tion for en­for­tum­ab ve­dotin

→ The AI ex­perts at No­table Labs have gar­nered an­oth­er $40 mil­lion to scale their au­to­mat­ed lab­o­ra­to­ry and an­a­lyt­ics plat­form. De­signed to match pa­tients to clin­i­cal tri­als by pre­dict­ing quick­ly who are most like­ly to re­spond to a can­cer drug, the start­up has pitched it­self as an ad­vo­cate for pa­tients and fa­cil­i­ta­tor to phar­ma com­pa­nies. With the Se­ries B cash, No­table Labs plans to ex­pand their plat­form both in terms of ge­og­ra­phy — build­ing labs out­side of North Amer­i­ca — and can­cer types (it’s cur­rent­ly fo­cused on hema­to­log­i­cal can­cers).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER